Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 97.4; 96.1 percentage of participants

Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098

Primary: Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis — -17.3; -66.2; -73.2 percent change — p=<0.0001

Primary: Evaluation of Overall Survival — 50.4 weeks

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis — -2.7; -54.8; -62.3; -71.7 percent change — p=<0.0001

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis — -5.1; -39.6; -64.2; -72.4 percent change — p=<0.0001

Primary: Maximum Observed Concentration in Plasma (Cmax) — 200; 290; 300; 580 ng/ml

Primary: Area Under the Plasma Concentration Curve (AUC) — 518; 470 mcg*hr/mL

Primary: 24 Hour Average and Maximum Testosterone Concentration — 262.3; 373.6; 298.3; 322.4 ng/dL — p=0.056

Primary: Objective Response Rate (ORR) — 16; 18; 16 percentage of participants

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis — -10.7; -28.9; -31.5; -42.5 percent change — p=0.0000

Primary: Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study — 0; 0; 0; 0 percentage of participants

Primary: Percent Mucociliary Clearance at 60 Minutes — 18.6; 15.4 percentage mucociliary clearance — p=0.62

Primary: Percentage of BCCs With Complete and at Least Partial Clinical Clearance — 92; 7; 83; 77 Percentage of BCCs

Primary: Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks — -4; -11; -13; -18 mg/dL — p=0.0670